Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 29, 2024 16:05 ET
|
Verve Therapeutics
BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,...
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
November 05, 2024 07:00 ET
|
Verve Therapeutics
Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025 First participant dosed in the Pulse-1...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024 16:26 ET
|
Verve Therapeutics
BOSTON , Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31,...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024 16:05 ET
|
Verve Therapeutics
BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on September 30,...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 03, 2024 16:05 ET
|
Verve Therapeutics
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on August 30,...
Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
August 08, 2024 07:00 ET
|
Verve Therapeutics
Heart-2 clinical trial of VERVE-102 enrolling in the U.K. and Canada; Clinical Trial Application cleared in Australia Heart-2 and PCSK9 program data update planned for first half of 2025 Phase...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024 16:05 ET
|
Verve Therapeutics
BOSTON, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on July 31, 2024,...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 01, 2024 16:05 ET
|
Verve Therapeutics
BOSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
June 28, 2024 07:00 ET
|
Verve Therapeutics
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 31, 2024 16:01 ET
|
Verve Therapeutics
BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...